MDWD News and Press, MediWound Ltd. From 08/09/22

MediWound press release ( NASDAQ: MDWD ): Q2 GAAP EPS of -$0.13 misses by $0.03 . Revenue of $4.67M (-22.8% Y/Y) misses by $0.61M . For further details see: MediWound GAAP EPS of -$0.13 misses by $0.03, revenue of $4.67M misses by $0.61M

Positive Results in Two Phase 2 Trial s of EscharEx FDA Assigned PDUFA Target Date of January 1 , 202 3 for NexoBrid BLA Enhance d the Board and L eadership T eam Conference C all...

Mr. N achum Shamir appointed as Chairman of the Board Dr. Robert Snyder appointed as Chief Medical Officer YAVNE, Israel, Aug. 08, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated b...

MediWound ( NASDAQ: MDWD ) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is -$0.10 (+16.7% Y/Y) and the consensus Revenue Estimate is $5.28M (-12.7% Y/Y). Over the last 1 year, MDWD has beaten EPS ...

The U.S. Food and Drug Administration (FDA) accepted for review MediWound's ( NASDAQ: MDWD ) re-submitted biologics license application (BLA) seeking approval of NexoBrid for eschar (dead tissue) removal (debridement) in adults with deep partial-thickness and/or full-...

YAVNE, Israel, Aug. 03, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the U.S. Food and Drug Admini...

Call Scheduled for Tuesday, August 9, 2022 at 8:30 AM Eastern Time YAVNE, Israel, Aug. 01, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, tod...

MW005 Shown to Be Safe and Well-Tolerated Target Lesions Clearance Data Provides Clinical Efficacy Proof-of-Concept YAVNE, Israel, July 11, 2022 (GLOBE NEWSWIRE) --  MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company ...

YAVNE, Israel, July 08, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced an oral presentation at the Advanced Wound Care Summit taking ...

Israeli biopharma MediWound ( NASDAQ: MDWD ) climbed ~13% in the pre-market Thursday after the company announced positive data from a Phase 2 trial designed to evaluate its wound candidate EscharEx as a therapy for the debridement of lower leg ulcers. The U.S.-based op...